Memantine: Updating a rare success story in pro-cognitive therapeutics

Parisa Karimi Tari, Chris G. Parsons, Graham L. Collingridge, Gerhard Rammes

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The great potential for NMDA receptor modulators as druggable targets in neurodegenerative disorders has been met with limited success. Considered one of the rare exceptions, memantine has consistently demonstrated restorative and prophylactic properties in many AD models. In clinical trials memantine slows the decline in cognitive performance associated with AD. Here, we provide an overview of the basic properties including pharmacological targets, toxicology and cellular effects of memantine. Evidence demonstrating reductions in molecular, physiological and behavioural indices of AD-like impairments associated with memantine treatment are also discussed. This represents both an extension and homage to Dr. Chris Parson's considerable contributions to our fundamental understanding of a success story in the AD treatment landscape.

Original languageEnglish
Article number109737
StatePublished - 15 Feb 2024
Externally publishedYes


  • Alzheimer's disease
  • Learning and memory
  • Memantine
  • NMDA receptor
  • Neuroprotection
  • Synaptic plasticity


Dive into the research topics of 'Memantine: Updating a rare success story in pro-cognitive therapeutics'. Together they form a unique fingerprint.

Cite this